OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

To reveal more filter options, please select whether you would like to review Active or Closed projects:

Clear
Organization: University of Arizona

4 Projects | 3 Researchers | $2,474,165 Invested

2024

University of Arizona

Roberta Brinton, PhD

Expanding AD Biomarkers in NIA funded PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial

  • Funding Amount: $1,774,201
  • Organization Type: Academic/Nonprofit
  • Program: Prevention
  • Target: Tau
  • Status: Active

2017

University of Arizona

Christopher Hulme, PhD

Optimization of selective DYRK1A inhibitors as a treatment for AD

  • Funding Amount: $99,964
  • Organization Type: Academic/Nonprofit
  • Program: Drug Discovery
  • Target: Tau
  • Status: Closed

2017

University of Arizona

Roberta Diaz Brinton, PhD

2017 Annual Goodes Prize for Excellence in Alzheimer's Drug Discovery: Allopregnanolone Novel Patentable Formulation to Advance Commercialization

  • Funding Amount: $150,000
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Neuronal Regeneration and Repair
  • Status: Closed

2016

University of Arizona

Roberta Diaz Brinton, PhD

Manufacturing of Allopregnanolone for Phase 2 Clinical Trial

  • Funding Amount: $450,000
  • Organization Type: Academic/Nonprofit
  • Program: Clinical
  • Target: Neuronal Regeneration and Repair
  • Status: Closed